The Lupus Research Alliance reports on the findings of the TULIP 2 Phase III study which demonstrated a potential new medicine [type 1 interferon] for lupus reduced disease activity versus placebo. TULIP 2 measured disease activity using an evaluation tool called the British Isles Lupus Assessment Group based Composite Lupus Assessment (BICLA). To meet the primary endpoint defined as a statistically significant and meaningful reduction in disease activity, BICLA requires improvement in organs affected by lupus with no new flares.

The Lupus Research Alliance quoted Mary K. Crow, MD, physician-in-chief and chief of rheumatology at HSS, and co-chair of the Lupus Research Alliance Scientific Advisory Board (SAB), about the impact of this research. “It is tremendously gratifying to learn of this important success,” said Dr. Crow. “The Lupus Research Alliance has made significant investments in research focused on the role of type I interferons in lupus, and I am personally very excited given my own research in this area,” she added.

Read the full article at Lupusresearch.org.